Rights issues hit 5-year high in FY26 amid market volatility

While the article doesn't directly address the pharma sector, the broader market volatility and FPI outflows could indirectly affect funding access for pharma companies, especially those looking for expansion or R&D capital. The shift towards promoter-backed funding might be a trend across various sectors, including pharma.

For pharma, focus on companies with strong balance sheets and consistent cash flows, as they may be better positioned to navigate capital market uncertainties. Look for companies with clear product pipelines and regulatory approvals.

For Indian markets, the practical takeaway is that this story carries a mixed read rather than a generic headline. Traders should judge it by actual market follow-through, not by narrative intensity alone.

Watch whether the market validates this read through price action, volume, and breadth. If the headline matters, the signal should show up in execution, not just in commentary.

• •Rights issues hit a 5-year high in FY26.
• •Promoter-backed funding is gaining traction.
• •Market volatility, tariff tensions, war jitters, and FPI outflows are reshaping capital-raising choices.
• •Risk flag: Increased market volatility could impact investor sentiment towards new pharma listings or secondary offerings.
• •Risk flag: Global geopolitical tensions might disrupt supply chains for raw materials, affecting pharma production costs and timelines.